Which Works Better: Semaglutide VS Tirzepatide 

 
 

Weight loss can seem like an overwhelming challenge, as it often becomes much more difficult and costly to maintain a healthy diet and adhere to a daily exercise routine. It's reassuring to know that in today's world, we have access to medications that can assist us in facing these overwhelming challenges. Everyone at this point has heard of Semaglutide and Tirzepatide or their class of drugs called GLP1’s. There is no doubt that we must do the hard work of exercising and consuming a healthy diet to lose weight, but it is nice to know that we have a tool that can help support and boost our efforts.

The main question we get asked is which medication works better, so in this post, I will try and break down some of the main points to make your decision easier.

Semaglutide and Tirzepatide are two novel pharmacological agents that have garnered significant attention in the realm of obesity. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the GLP-1 hormone and can help individuals feel less hungry. In contrast, Tirzepatide is a dual agonist, acting on both the GLP-1 and glucosedependent insulinotropic polypeptide (GIP) receptors. The GIP hormone can also trigger insulin creation and sensations of fullness.

Traditionally, a major barrier to the use of GLP-1 receptor agonists has been the need for subcutaneous injections, which can be inconvenient for many individuals. The availability of an oral formulation of Semaglutide has been a significant advancement, as it offers a more convenient route of administration that may improve patient adherence and acceptance.

Semaglutide has been found to have gastrointestinal (GI) side effects in 82% of cases, whereas Tirzepatide has reported GI side effects in only 42% of cases. It is worth noting that Tirzepatide is associated with fewer GI side effects compared to Semaglutide. Additionally, over a period of 65 weeks, Semaglutide has been shown to result in a weight loss of 10% of body weight, while Tirzepatide has demonstrated a weight loss of 15% of body weight over 72 weeks.

Tirzepatide surpasses Semaglutide in terms of efficacy and tolerability. However, the cost of both medications has posed a challenge as insurance companies often refuse coverage for weight loss purposes. Fortunately, compounding pharmacies offer these medications at reduced prices. Patients consistently achieve remarkable outcomes with compounded medications, and Lotus Weight Loss and Wellness remains committed to providing the necessary support for individuals facing the daunting task of weight loss, at the most affordable cost possible. 



Christie Conley
MSN, APRN-BC Co-Founder, Medical Director, Provider